Supernus Pharmaceuticals (SUPN) Total Debt (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 9 years of Total Debt data on file, last reported at $31.1 million in Q4 2025.

• On a quarterly basis, Total Debt fell 34.41% year-over-year to $31.1 million in Q4 2025; TTM through Dec 2025 was $31.1 million, a 34.41% decrease from a year earlier, with the FY2025 full-year figure at $31.1 million, down 34.41% from the prior year.
• Total Debt for Q4 2025 stood at $31.1 million, up from $11.2 million in the prior quarter.
• Over the last five years, Total Debt for SUPN reached as high as $424.1 million in Q4 2021 and fell as low as $11.2 million in Q3 2025.
• Historically, Total Debt has averaged $59.3 million across 5 years, with a median of $46.6 million in 2024.
• Across the five-year window, Total Debt soared 1272.47% in 2021 and slumped 95.02% in 2022, its largest moves.
• Year by year, Total Debt stood at $424.1 million in 2021, then slumped by 95.02% to $21.1 million in 2022, then soared by 146.54% to $52.1 million in 2023, then dropped by 9.08% to $47.3 million in 2024, then plunged by 34.41% to $31.1 million in 2025.
• Per Business Quant data, the three most recent Total Debt figures were $31.1 million in Q4 2025, $11.2 million in Q3 2025, and $30.0 million in Q1 2025.